Qube Research & Technologies (QRT)’s Arcutis Biotherapeutics ARQT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.48M	Sell	361,662 -362,405	-50%	-$8.44M	0.01%	1317
2026 Q1	$17.1M	Buy	724,067 +62,652	+9%	+$1.6M	0.02%	963
2025 Q4	$19.2M	Sell	661,415 -153,152	-19%	-$3.92M	0.02%	937
2025 Q3	$15.4M	Buy	814,567 +237,074	+41%	+$3.74M	0.02%	1039
2025 Q2	$8.1M	Buy	577,493 +385,274	+200%	+$5.4M	0.01%	1419
2025 Q1	$3.01M	Buy	+192,219	New	+$2.71M	﹤0.01%	1790
2024 Q4	–	Sell	-20,432	Closed	-$190K	–	3438
2024 Q3	$190K	Buy	+20,432	New	+$202K	﹤0.01%	2605
2024 Q1	–	Sell	-725,894	Closed	-$2.34M	–	4446
2023 Q4	$2.34M	Buy	+725,894	New	+$1.97M	﹤0.01%	1444
2023 Q3	–	Sell	-13,631	Closed	-$130K	–	4079
2023 Q2	$130K	Sell	13,631 -6,901	-34%	-$76.6K	﹤0.01%	1895
2023 Q1	$226K	Sell	20,532 -37,752	-65%	-$546K	﹤0.01%	1889
2022 Q4	$863K	Buy	+58,284	New	+$1.02M	﹤0.01%	1285

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ARQT Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Arcutis Biotherapeutics (ARQT) stake by 50% in Q2 2026, selling an estimated $8.44M and leaving 361,662 shares worth $9.48M. The position accounts for 0.01% of the portfolio, ranked #1317.

Qube Research & Technologies (QRT) first reported a position in ARQT in Q4 2022 and has held it in 11 quarters since. The position peaked at $19.2M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Qube Research & Technologies (QRT) held 361,662 shares of Arcutis Biotherapeutics worth $9.48M as of Q2 2026.
Qube Research & Technologies (QRT) sold 362,405 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.44M.
Arcutis Biotherapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1317 holding.
Qube Research & Technologies (QRT) first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 11 quarters since.
Qube Research & Technologies (QRT)'s Arcutis Biotherapeutics position peaked at $19.2M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.